{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:33:17Z","timestamp":1793028797724,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04358-0","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:20:22Z","timestamp":1761571222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of GLP-1 receptor agonists and dual GLP-1\/GIP receptor agonists in managing MAFLD: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3003-5226","authenticated-orcid":false,"given":"Surtika","family":"Tamilwanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7113-9323","authenticated-orcid":false,"given":"Zoriah","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6090-6361","authenticated-orcid":false,"given":"Lim Yan","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0125-2683","authenticated-orcid":false,"given":"Ahmad Naoras","family":"Bitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-3552","authenticated-orcid":false,"given":"Raghdaa Hamdan Al","family":"Zarzour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8732-1883","authenticated-orcid":false,"given":"Salah A.","family":"Alshehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"4358_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/J.JHEP.2023.04.036","volume":"79","author":"VWS Wong","year":"2023","unstructured":"Wong VWS, Ekstedt M, Wong GLH, Hagstr\u00f6m H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79:842\u201352. https:\/\/doi.org\/10.1016\/J.JHEP.2023.04.036.","journal-title":"J Hepatol"},{"key":"4358_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4358_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/S12916-024-03315-0","author":"L Cao","year":"2024","unstructured":"Cao L, An Y, Liu H, Jiang J, Liu W, Zhou Y, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis. BMC Med. 2024. https:\/\/doi.org\/10.1186\/S12916-024-03315-0.","journal-title":"BMC Med"},{"key":"4358_CR4","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/CVR\/CVAD095","volume":"119","author":"C Grander","year":"2023","unstructured":"Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119:1787\u201398. https:\/\/doi.org\/10.1093\/CVR\/CVAD095.","journal-title":"Cardiovasc Res"},{"key":"4358_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400:1803\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(22)01655-5.","journal-title":"Lancet"},{"key":"4358_CR6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/J.GASTRO.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1. https:\/\/doi.org\/10.1053\/J.GASTRO.2019.11.312.","journal-title":"Gastroenterology"},{"key":"4358_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/HEP.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u201333. https:\/\/doi.org\/10.1002\/HEP.29466.","journal-title":"Hepatology"},{"key":"4358_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102377","volume":"48","author":"SA Alshehade","year":"2024","unstructured":"Alshehade SA. Resmetirom\u2019s approval: highlighting the need for comprehensive approaches in NASH therapeutics. Clin Res Hepatol Gastroenterol. 2024;48:102377. https:\/\/doi.org\/10.1016\/j.clinre.2024.102377.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"4358_CR9","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/S40519-021-01287-1","volume":"27","author":"G Marchesini","year":"2022","unstructured":"Marchesini G, Bugianesi E, Burra P, Marra F, Miele L, Alisi A, et al. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian association for the study of the liver (AISF), the Italian society of diabetology (SID) and the Italian society of obesity (SIO). Eat Weight Disord. 2022;27:1603\u201319. https:\/\/doi.org\/10.1007\/S40519-021-01287-1.","journal-title":"Eat Weight Disord"},{"key":"4358_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/HEP.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328\u201357. https:\/\/doi.org\/10.1002\/HEP.29367.","journal-title":"Hepatology"},{"key":"4358_CR11","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/J.DRUDIS.2017.06.007","volume":"22","author":"HH Hansen","year":"2017","unstructured":"Hansen HH, Feigh M, Veidal SS, Rigbolt KT, Vrang N, Fosgerau K. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today. 2017;22:1707\u201318. https:\/\/doi.org\/10.1016\/J.DRUDIS.2017.06.007.","journal-title":"Drug Discov Today"},{"key":"4358_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS24021703","author":"R Nevola","year":"2023","unstructured":"Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/IJMS24021703.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4358_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/J.CMET.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356. https:\/\/doi.org\/10.1016\/J.CMET.2018.03.001.","journal-title":"Cell Metab"},{"key":"4358_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X.","journal-title":"Lancet"},{"key":"4358_CR15","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/IUB.2760","volume":"75","author":"X Yu","year":"2023","unstructured":"Yu X, Bian X, Zhang H, Yang S, Cui D, Su Z. Liraglutide ameliorates hepatic steatosis via retinoic acid receptor-related orphan receptor \u03b1-mediated autophagy pathway. IUBMB Life. 2023;75:856\u201367. https:\/\/doi.org\/10.1002\/IUB.2760.","journal-title":"IUBMB Life"},{"key":"4358_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/J.TRSL.2020.07.008","volume":"227","author":"E Somm","year":"2021","unstructured":"Somm E, Montandon SA, Loizides-Mangold U, Ga\u00efa N, Lazarevic V, De Vito C, et al. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. Transl Res. 2021;227:75\u201388. https:\/\/doi.org\/10.1016\/J.TRSL.2020.07.008.","journal-title":"Transl Res"},{"key":"4358_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8936865","author":"S Rezaei","year":"2021","unstructured":"Rezaei S, Tabrizi R, Nowrouzi-Sohrabi P, Jalali M, Atkin SL, Al-Rasadi K, et al. GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1155\/2021\/8936865.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"4358_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-01663-y","volume":"11","author":"S Ghosal","year":"2021","unstructured":"Ghosal S, Datta D, Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep. 2021;11:1\u20138. https:\/\/doi.org\/10.1038\/s41598-021-01663-y.","journal-title":"Scientific Reports."},{"key":"4358_CR19","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/DC19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, et al. Effects of novel dual GIP and GLP-1 receptor agonist Tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43:1352\u20135. https:\/\/doi.org\/10.2337\/DC19-1892.","journal-title":"Diabetes Care"},{"key":"4358_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-021-01412-5","author":"EZ Fisman","year":"2021","unstructured":"Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021. https:\/\/doi.org\/10.1186\/S12933-021-01412-5.","journal-title":"Cardiovasc Diabetol"},{"key":"4358_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/J.DIABET.2019.12.007","volume":"46","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials. Diabetes Metab. 2020;46:427\u201341. https:\/\/doi.org\/10.1016\/J.DIABET.2019.12.007.","journal-title":"Diabetes Metab"},{"key":"4358_CR22","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/S12072-023-10568-Z","volume":"17","author":"K Vaz","year":"2023","unstructured":"Vaz K, Clayton-Chubb D, Majeed A, Lubel J, Simmons D, Kemp W, et al. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatol Int. 2023;17:1082\u201397. https:\/\/doi.org\/10.1007\/S12072-023-10568-Z.","journal-title":"Hepatol Int"},{"key":"4358_CR23","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"4358_CR24","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. Aasld practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"key":"4358_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/BMJ.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/BMJ.327.7414.557.","journal-title":"BMJ"},{"key":"4358_CR26","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. https:\/\/doi.org\/10.1136\/BMJ.N71.","DOI":"10.1136\/BMJ.N71"},{"key":"4358_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic Dysfunction\u2013Associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299\u2013310. https:\/\/doi.org\/10.1056\/NEJMOA2401943\/. http:\/\/SUPPL_FILE\/NEJMOA2401943_DATA-SHARING.PDF .","journal-title":"N Engl J Med"},{"key":"4358_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMOA2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311\u20139. https:\/\/doi.org\/10.1056\/NEJMOA2401755.","journal-title":"N Engl J Med"},{"key":"4358_CR29","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/J.CGH.2024.04.017","volume":"22","author":"SS Shankar","year":"2024","unstructured":"Shankar SS, Daniels SJ, Robertson D, Sarv J, S\u00e1nchez J, Carter D, et al. Safety and efficacy of novel incretin Co-agonist cotadutide in Biopsy-proven noncirrhotic MASH with fibrosis. Clin Gastroenterol Hepatol. 2024;22:1847\u2013e185711. https:\/\/doi.org\/10.1016\/J.CGH.2024.04.017.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4358_CR30","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/J.JHEP.2023.05.013","volume":"79","author":"M Romero-G\u00f3mez","year":"2023","unstructured":"Romero-G\u00f3mez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of Efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023;79:888\u201397. https:\/\/doi.org\/10.1016\/J.JHEP.2023.05.013.","journal-title":"J Hepatol"},{"key":"4358_CR31","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/LIV.14065","volume":"39","author":"J Khoo","year":"2019","unstructured":"Khoo J, Hsiang JC, Taneja R, Koo SH, Soon GH, Kam CJ, et al. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int. 2019;39:941\u20139. https:\/\/doi.org\/10.1111\/LIV.14065.","journal-title":"Liver Int"},{"key":"4358_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/1753-0407.12555","volume":"9","author":"W Feng","year":"2017","unstructured":"Feng W, Gao C, Bi Y, Wu M, Li P, Shen S, et al. Randomized trial comparing the effects of gliclazide, liraglutide, and Metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes. 2017;9:800\u20139. https:\/\/doi.org\/10.1111\/1753-0407.12555.","journal-title":"J Diabetes"},{"key":"4358_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/DMRR.3292","author":"L Liu","year":"2020","unstructured":"Liu L, Yan H, Xia MF, Zhao L, Lv M, Zhao N, et al. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev. 2020. https:\/\/doi.org\/10.1002\/DMRR.3292.","journal-title":"Diabetes Metab Res Rev"},{"key":"4358_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108487","author":"W Guo","year":"2020","unstructured":"Guo W, Tian W, Lin L, Xu X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. Diabetes Res Clin Pract. 2020. https:\/\/doi.org\/10.1016\/j.diabres.2020.108487.","journal-title":"Diabetes Res Clin Pract"},{"key":"4358_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1210\/JC.2016-2775","volume":"102","author":"JM Petit","year":"2017","unstructured":"Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD study. J Clin Endocrinol Metab. 2017;102:407\u201315. https:\/\/doi.org\/10.1210\/JC.2016-2775.","journal-title":"J Clin Endocrinol Metab"},{"key":"4358_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.diabres.2015.12.003","volume":"113","author":"S Savvidou","year":"2016","unstructured":"Savvidou S, Karatzidou K, Tsakiri K, Gagalis A, Hytiroglou P, Goulis J. Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide. Diabetes Res Clin Pract. 2016;113:125\u201334. https:\/\/doi.org\/10.1016\/j.diabres.2015.12.003.","journal-title":"Diabetes Res Clin Pract"},{"key":"4358_CR37","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181304","author":"F Tian","year":"2018","unstructured":"Tian F, Zheng Z, Zhang D, He S, Shen J. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. Biosci Rep. 2018. https:\/\/doi.org\/10.1042\/BSR20181304.","journal-title":"Biosci Rep"},{"key":"4358_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/JDI.12888","volume":"10","author":"WH Feng","year":"2019","unstructured":"Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM, et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial. J Diabetes Investig. 2019;10:399\u2013407. https:\/\/doi.org\/10.1111\/JDI.12888.","journal-title":"J Diabetes Investig"},{"key":"4358_CR39","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1590\/S0004-27302013000900005","volume":"57","author":"H Fan","year":"2013","unstructured":"Fan H, Pan Q, Xu Y, Yang X. Exenatide melhora o diabetes Tipo 2 de ocorr\u00eancia concomitante com doen\u00e7a hep\u00e1tica gordurosa n\u00e3o alco\u00f3lica. Arq Bras Endocrinol Metabol. 2013;57:702\u20138. https:\/\/doi.org\/10.1590\/S0004-27302013000900005.","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"4358_CR40","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/J.CLINRE.2020.01.007","volume":"44","author":"LY Zhang","year":"2020","unstructured":"Zhang LY, Qu XN, Sun ZY, Zhang Y. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2020;44:674\u201380. https:\/\/doi.org\/10.1016\/J.CLINRE.2020.01.007.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"4358_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-019-45593-2","author":"HJ van Eyk","year":"2019","unstructured":"van Eyk HJ, Blauw LL, Bizino MB, Wang Y, van Dijk KW, de Mutsert R, et al. Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort. Sci Rep. 2019. https:\/\/doi.org\/10.1038\/S41598-019-45593-2.","journal-title":"Sci Rep"},{"key":"4358_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/S00125-019-05021-6","volume":"63","author":"MB Bizino","year":"2020","unstructured":"Bizino MB, Jazet IM, de Heer P, van Eyk HJ, Dekkers IA, Rensen PCN, et al. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia. 2020;63:65\u201374. https:\/\/doi.org\/10.1007\/S00125-019-05021-6.","journal-title":"Diabetologia"},{"key":"4358_CR43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/DOM.13487","volume":"21","author":"N Matikainen","year":"2019","unstructured":"Matikainen N, S\u00f6derlund S, Bj\u00f6rnson E, Pietil\u00e4inen K, Hakkarainen A, Lundbom N, et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study. Diabetes Obes Metab. 2019;21:84\u201394. https:\/\/doi.org\/10.1111\/DOM.13487.","journal-title":"Diabetes Obes Metab"},{"key":"4358_CR44","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/nejmoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113\u201324. https:\/\/doi.org\/10.1056\/nejmoa2028395.","journal-title":"N Engl J Med"},{"key":"4358_CR45","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","volume":"54","author":"A Flint","year":"2021","unstructured":"Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021;54:1150\u201361. https:\/\/doi.org\/10.1111\/apt.16608.","journal-title":"Aliment Pharmacol Ther"},{"key":"4358_CR46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/APT.17598","volume":"58","author":"M Romero-G\u00f3mez","year":"2023","unstructured":"Romero-G\u00f3mez M, Armstrong MJ, Funuyet-Salas J, Mangla KK, Ladelund S, Sejling AS, et al. Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial. Aliment Pharmacol Ther. 2023;58:395\u2013403. https:\/\/doi.org\/10.1111\/APT.17598.","journal-title":"Aliment Pharmacol Ther"},{"key":"4358_CR47","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kj\u00e6r MS, Krarup N, et al. Semaglutide 2\u00b74\u00a0mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511\u201322. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4358_CR48","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMOA2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 trial of semaglutide in metabolic Dysfunction\u2013Associated steatohepatitis. N Engl J Med. 2025;392:2089\u201399. https:\/\/doi.org\/10.1056\/NEJMOA2413258.","journal-title":"N Engl J Med"},{"key":"4358_CR49","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1111\/DOM.13007","volume":"19","author":"J Khoo","year":"2017","unstructured":"Khoo J, Hsiang J, Taneja R, Law NM, Ang TL. Comparative effects of liraglutide 3\u00a0mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial. Diabetes Obes Metab. 2017;19:1814\u20137. https:\/\/doi.org\/10.1111\/DOM.13007.","journal-title":"Diabetes Obes Metab"},{"key":"4358_CR50","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/S00125-020-05265-7","volume":"63","author":"MS Kuchay","year":"2020","unstructured":"Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS, et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia. 2020;63:2434\u201345. https:\/\/doi.org\/10.1007\/S00125-020-05265-7.","journal-title":"Diabetologia"},{"key":"4358_CR51","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1007\/S00125-016-4100-7","volume":"59","author":"MM Smits","year":"2016","unstructured":"Smits MM, Tonneijck L, Muskiet MHA, Kramer MHH, Pouwels PJW, van den Pieters- Bos IC, et al. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia. 2016;59:2588\u201393. https:\/\/doi.org\/10.1007\/S00125-016-4100-7.","journal-title":"Diabetologia"},{"key":"4358_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01604-7","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2018Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022. https:\/\/doi.org\/10.1186\/s12933-022-01604-7.","journal-title":"Cardiovasc Diabetol"},{"key":"4358_CR53","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","volume":"65","author":"T Karagiannis","year":"2022","unstructured":"Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65:1251\u201361. https:\/\/doi.org\/10.1007\/s00125-022-05715-4.","journal-title":"Diabetologia"},{"key":"4358_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.163","volume":"3","author":"X Lv","year":"2020","unstructured":"Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): a systematic review. Endocrinology, Diabetes & Metabolism. 2020;3:e00163. https:\/\/doi.org\/10.1002\/edm2.163.","journal-title":"Endocrinology, Diabetes & Metabolism"},{"key":"4358_CR55","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pcd.2024.03.005","volume":"18","author":"L Fang","year":"2024","unstructured":"Fang L, Li J, Zeng H, Liu J. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: a systematic review and meta-analysis. Prim Care Diabetes. 2024;18:268\u201376. https:\/\/doi.org\/10.1016\/j.pcd.2024.03.005.","journal-title":"Prim Care Diabetes"},{"key":"4358_CR56","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","volume":"35","author":"JE Campbell","year":"2023","unstructured":"Campbell JE, M\u00fcller TD, Finan B, DiMarchi RD, Tsch\u00f6p MH, D\u2019Alessio DA. GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss\u2014chemistry, physiology, and clinical applications. Cell Metab. 2023;35:1519\u201329. https:\/\/doi.org\/10.1016\/j.cmet.2023.07.010.","journal-title":"Cell Metab"},{"key":"4358_CR57","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","volume":"36","author":"A Regmi","year":"2024","unstructured":"Regmi A, Aihara E, Christe ME, Varga G, Beyer TP, Ruan X, et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab. 2024;36:1534\u2013e15497. https:\/\/doi.org\/10.1016\/j.cmet.2024.05.010.","journal-title":"Cell Metab"},{"key":"4358_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50328-5","author":"HH Hansen","year":"2023","unstructured":"Hansen HH, Pors S, Andersen MW, Vyberg M, N\u00f8hr-Meldgaard J, Nielsen MH, et al. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis. Sci Rep. 2023. https:\/\/doi.org\/10.1038\/s41598-023-50328-5.","journal-title":"Sci Rep"},{"key":"4358_CR59","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.3748\/wjg.v30.i48.5205","volume":"30","author":"A Singh","year":"2024","unstructured":"Singh A, Sohal A, Batta A. GLP-1, GIP\/GLP-1, and GCGR\/GLP-1 receptor agonists: novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol. 2024;30:5205\u201311. https:\/\/doi.org\/10.3748\/wjg.v30.i48.5205.","journal-title":"World J Gastroenterol"},{"key":"4358_CR60","doi-asserted-by":"publisher","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 trial of semaglutide in metabolic Dysfunction-Associated steatohepatitis. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMOA2413258\/. http:\/\/SUPPL_FILE\/NEJMOA2413258_DATA-SHARING.PDF.","DOI":"10.1056\/NEJMOA2413258\/"},{"key":"4358_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00599-1","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-J\u00e4rvinen H, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025. https:\/\/doi.org\/10.1038\/s41572-025-00599-1.","journal-title":"Nat Rev Dis Primers"},{"key":"4358_CR62","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/nejmoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/nejmoa2309000.","journal-title":"N Engl J Med"},{"key":"4358_CR63","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037\u201348. https:\/\/doi.org\/10.1038\/s41591-024-03018-2.","journal-title":"Nat Med"},{"issue":"S1","key":"4358_CR64","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(S1):5\u201321. https:\/\/doi.org\/10.1111\/dom.13129.","journal-title":"Diabetes Obes Metab"},{"key":"4358_CR65","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47:1873\u201388. https:\/\/doi.org\/10.2337\/dci24-0003.","journal-title":"Diabetes Care"},{"key":"4358_CR66","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S2468-1253(23)00453-3","volume":"9","author":"PN Brennan","year":"2024","unstructured":"Brennan PN, Tavabie OD, Li W, Marjot T, Corless L, Fallowfield JA, et al. Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice. Lancet Gastroenterol Hepatol. 2024;9:577\u201382. https:\/\/doi.org\/10.1016\/S2468-1253(23)00453-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4358_CR67","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u201365. https:\/\/doi.org\/10.1002\/hep.29085.","journal-title":"Hepatology"},{"key":"4358_CR68","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/dom.13553","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain SC, Mosenzon O, Arechavaleta R, Bogda\u0144ski P, Comlekci A, Consoli A, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2019;21:499\u2013508. https:\/\/doi.org\/10.1111\/dom.13553.","journal-title":"Diabetes Obes Metab"},{"key":"4358_CR69","doi-asserted-by":"publisher","first-page":"e69129","DOI":"10.7759\/cureus.69129","volume":"16","author":"SP Kakde","year":"2024","unstructured":"Kakde SP, Mushtaq M, Liaqat M, Ali H, Mushtaq MM, Sarwer MA, et al. Emerging therapies for Non-Alcoholic steatohepatitis (NASH): A comprehensive review of Pharmacological and Non-Pharmacological approaches. Cureus. 2024;16:e69129. https:\/\/doi.org\/10.7759\/cureus.69129.","journal-title":"Cureus"},{"key":"4358_CR70","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","volume":"184","author":"F Kanwal","year":"2024","unstructured":"Kanwal F, Kramer JR, Li L, Yang YX, Cao Y, Yu X, et al. GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. JAMA Intern Med. 2024;184:1314\u201323. https:\/\/doi.org\/10.1001\/jamainternmed.2024.4661.","journal-title":"JAMA Intern Med"},{"key":"4358_CR71","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/apt.17925","volume":"59","author":"MI Elsaid","year":"2024","unstructured":"Elsaid MI, Li N, Firkins SA, Rustgi VK, Paskett ED, Acharya C, et al. Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Aliment Pharmacol Ther. 2024;59:1096\u2013110. https:\/\/doi.org\/10.1111\/apt.17925.","journal-title":"Aliment Pharmacol Ther"},{"key":"4358_CR72","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"key":"4358_CR73","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4358_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1149328","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang Q, Tan Y, Chen Y, Zhou X, Liu S, et al. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Front Endocrinol (Lausanne). 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1149328.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4358_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1509947","volume":"12","author":"X Huang","year":"2025","unstructured":"Huang X, Wu M, Huang B, Zhang Y. Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Front Med. 2025;12:1509947. https:\/\/doi.org\/10.3389\/fmed.2025.1509947.","journal-title":"Front Med"},{"key":"4358_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2024","unstructured":"Song SJ, Lai JCT, Wong GLH, Wong VWS, Yip TCF. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80:e54. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.021.","journal-title":"J Hepatol"},{"key":"4358_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100915","author":"C Akbari","year":"2024","unstructured":"Akbari C, Dodd M, St\u00e5l P, Nasr P, Ekstedt M, Kechagias S, et al. Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD. JHEP Rep. 2024. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100915.","journal-title":"JHEP Rep"},{"key":"4358_CR78","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/nejmoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/nejmoa2307563.","journal-title":"N Engl J Med"},{"key":"4358_CR79","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/nejmoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109\u201321. https:\/\/doi.org\/10.1056\/nejmoa2403347.","journal-title":"N Engl J Med"},{"key":"4358_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156043","author":"RT Lin","year":"2024","unstructured":"Lin RT, Sun QM, Xin X, Ng CH, Valenti L, Hu YY, et al. Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and pan-PPAR agonists for MASLD: a systematic review and network meta-analysis. Metabolism. 2024. https:\/\/doi.org\/10.1016\/j.metabol.2024.156043.","journal-title":"Metabolism"},{"key":"4358_CR81","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/apt.70196","volume":"61","author":"M Zafer","year":"2025","unstructured":"Zafer M, Tavaglione F, Romero-G\u00f3mez M, Loomba R, Review Article. GLP-1 receptor agonists and Glucagon\/GIP\/GLP-1 receptor dual or triple agonists\u2014Mechanism of action and emerging therapeutic landscape in MASLD. Aliment Pharmacol Ther. 2025;61:1872\u201388. https:\/\/doi.org\/10.1111\/apt.70196.","journal-title":"Aliment Pharmacol Ther"},{"key":"4358_CR82","doi-asserted-by":"publisher","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384. https:\/\/doi.org\/10.1136\/bmj-2023-076410.","DOI":"10.1136\/bmj-2023-076410"},{"key":"4358_CR83","doi-asserted-by":"publisher","unstructured":"Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, et al. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ. 2017;357. https:\/\/doi.org\/10.1136\/bmj.j2499.","DOI":"10.1136\/bmj.j2499"},{"key":"4358_CR84","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, Kita Y, Takata N, Tsujiguchi H, et al. Comparison of Tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care. 2022;45:2064\u201375. https:\/\/doi.org\/10.2337\/dc21-2049.","journal-title":"Diabetes Care"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04358-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04358-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04358-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:46:23Z","timestamp":1793025983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04358-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4358"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04358-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This systematic review and meta-analysis utilized only previously published data from randomized controlled trials. No primary data collection involving human participants was conducted as part of this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"765"}}